Tumor indoleamine 2,3-dioxygenase (IDO) inhibits CD19-CAR T cells and is downregulated by lymphodepleting drugs

Although T cells expressing CD19-specific chimeric antigen receptors (CARs) are a promising new therapy for B-cell malignancies, objective responses are observed at lower frequencies in patients with lymphoma than in those with acute B-cell leukemia. We postulated that the tumor microenvironment sup...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Blood
Main Authors: Ninomiya, Soranobu, Narala, Neeharika, Huye, Leslie, Yagyu, Shigeki, Savoldo, Barbara, Dotti, Gianpietro, Heslop, Helen E., Brenner, Malcolm K., Rooney, Cliona M., Ramos, Carlos A.
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Hematology 2015
Assuntos:
Immunobiology
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4473118/
https://ncbi.nlm.nih.gov/pubmed/25940712
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2015-01-621474
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados